Stopped: Study was discontinued due to lack of recruitment.
This is a sequential Phase I and IIa study to identify the maximum tolerated dose and to evaluate safety, tolerability, toxicity, pharmacokinetics and pharmacodynamics of the oral sphingosine kinase inhibitor ABC294640 specifically in patients with diffuse large B-cell lymphoma (DLBCL), including virus-associated (e.g., KSHV- or EBV-associated) DLBCL or Kaposi Sarcoma (KS) after failure of or intolerance to initial standard therapy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Determine Maximum tolerated dose (MTD) of ABC294640 in patients with refractory/relapsed DLBCL or KS and determine tolerability at MTD.
Timeframe: Patients will be followed until a dose limiting toxicity (DLT) is experienced, if present, expected within the first 8 weeks
Evaluate safety of ABC294640 in patients with refractory/relapsed DLBCL or KS
Timeframe: If present, expected within 8 weeks